Avidity Partners Management’s Akero Therapeutics AKRO Stock Holding History

Avidity Partners Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-40,500	Closed	-$1.92M	–	41
2025 Q3	$1.92M	Sell	40,500 -93,500	-70%	-$4.53M	0.44%	40
2025 Q2	$7.15M	Buy	134,000 +77,000	+135%	+$3.5M	1.42%	24
2025 Q1	$2.31M	Sell	57,000 -25,000	-30%	-$1.06M	0.44%	52
2024 Q4	$2.28M	Buy	+82,000	New	+$2.48M	0.22%	56
2024 Q1	–	Sell	-235,000	Closed	-$5.49M	–	92
2023 Q4	$5.49M	Sell	235,000 -504,100	-68%	-$9.94M	0.2%	65
2023 Q3	$37.4M	Sell	739,100 -285,900	-28%	-$13.3M	1.51%	31
2023 Q2	$47.9M	Sell	1,025,000 -1,422,000	-58%	-$65.2M	1.67%	21
2023 Q1	$93.6M	Sell	2,447,000 -1,378,000	-36%	-$61.4M	3.11%	7
2022 Q4	$210M	Buy	3,825,000 +703,000	+23%	+$30.1M	4.54%	5
2022 Q3	$106M	Buy	+3,122,000	New	+$47.8M	2.16%	13

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avidity Partners Management's AKRO Position: Q4 2025 in Review

Avidity Partners Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 40,500 shares — an estimated $1.92M sold.

Avidity Partners Management first reported a position in AKRO in Q3 2022 and held it in 10 quarters. The position peaked at $210M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Avidity Partners Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Avidity Partners Management sold 40,500 Akero Therapeutics shares in Q4 2025, an estimated $1.92M.
Avidity Partners Management first reported a position in Akero Therapeutics in Q3 2022 and held it in 10 quarters.
Avidity Partners Management's Akero Therapeutics position peaked at $210M in Q4 2022.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.